Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs US Bancorp (USB) Price & Performance

Heron Therapeutics IncTrade
US BancorpTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs US Bancorp — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while US Bancorp trades at $57.18 (market cap $87.52B). The key difference: US Bancorp is far larger — about 1182.1× Heron Therapeutics Inc's market cap, and US Bancorp pays a 3.85% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and US Bancorp for 97 Days on average.

HRTXUSB
Market Cap
$74.04M$87.52B
Volume
3,668,0959,184,647
Sector
HealthFinancials
52-Week High
$1.49$65.42
52-Week Low
$0.27$45.28
Typical Hold Time
35 Days97 Days
Enterprise Value
$180.78M$117.01B
Dividend Yield
—3.85%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.

The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.

US Bancorp

U.S. Bancorp (USB) trades at $56.17, down 1.95% on the day, with a bearish technical outlook despite strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. USB maintains robust profitability with a 27.61% net income margin and attractive valuation metrics including a P/E of 11.21. Recent news highlights dividend increases and positive business momentum in payments and capital markets.

The stock presents a compelling value opportunity with analyst consensus target of $69.94 (24.5% upside), though technical indicators signal near-term caution. Key risks include interest rate sensitivity and regulatory changes, while institutional sentiment remains positive with 51% buy ratings. The upcoming Q3 earnings report will be critical for confirming the positive fundamental trajectory.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HRTX
8% Buy92% Sell
Avg holding period · 35 Days
USB
28% Buy72% Sell
Avg holding period · 97 Days

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX →

About US Bancorp

As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.

Read more on USB →